- Home
- CTRM vs BCAB Comparison
CTRM vs BCAB Comparison
Compare CTRM & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | BCAB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 20.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTRM | BCAB |
|---|---|---|
| Price | $2.20 | $0.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 81.2K | ★ 3.1M |
| Earning Date | 12-03-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,412,579.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.84 | $0.14 |
| 52 Week High | $2.92 | $1.43 |
Technical Indicators
Market Signals| Indicator | CTRM | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 26.33 |
| Support Level | $2.12 | $0.15 |
| Resistance Level | $2.39 | $0.21 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 23.56 | 1.63 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.